

Clean Science and Technology Limited

nnovationatwork

Date: 07.02.2022

To,

BSE Limited
Phiroze JeeJeebhoy Towers,
Dalal Street,
Fort, Mumbai – 400 001
Scrip Code: 543318

National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051 Trading Symbol: CLEAN

Dear Sir/Madam,

Subject: Investor Presentation.

In accordance with Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Financial Results presentation for quarter and nine months ended 31st December, 2021 is enclosed.

The aforesaid presentation is also available on the Company's website.

You are requested to take the same on record.

Thanking You.

For Clean Science and Technology Limited

Mahesh Kulkarni Company Secretary

Q)



Clean Science and Technology Limited

innovationatwork

Q3 FY 2022 RESULTS PRESENTATION February 2022




KEY UPDATES DURING THE QUARTER





Mixed quarter

- Recorded highest ever revenue and PAT in Q3 FY2022. Total revenues increased by 18% and 44% on Q-o-Q and Y-o-Y basis respectively
- Despite end product price hike, gross margins impacted as raw material price increase was steeper during Q3. Other key factors impacting margins are coal prices and moderation in product mix with pharma segment share significantly higher in Q3 compared to Q2



	Q3 FY2022	Q2 FY2022	Q3 FY2021
Sale of products	100.0%	100.0%	100.0%
Raw material	35.5%	31.7%	24.3%
Gross margin	64.5%	68.3%	75.7%
Power & Fuel	9.9%	7.9%	6.8%

Focus on sustainability

- Company has been awarded the "Greenco Silver" rating by GreenCo Green Company Rating System. Clean Science and Technology Limited is the first specialty chemical company in the country to be given the "Greenco" certification
- This rating is a clear validation of our company's emphasis on clean, green and sustainable practices and processes

Product launch and capex

- Commissioned plants for manufacturing PBQ (Para benzoquinone), BHA and TBHQ. PBQ is an import substitute with Clean Science being the only company in India to manufacture PBQ
- Cash capex of ~INR 110 crore cumulatively during 9M FY2022, all funded from internal accruals

P&L OVERVIEW – STEADY REVENUE GROWTH

Margins subdued due to continued inflationary environment




Particulars (INR Crore)	Q3 FY 2022	Q2 FY 2022	Q-o-Q (%)	Q3 FY 2021	Y-o-Y (%)	9M FY 2022	9M FY 2021	Y-o-Y (%)
Revenue from product sales	178.2	151.7	18%	124.3	43%	474.6	374.5	27%
Other operating income	2.6	1.5		1.1		5.7	4.0	
Total Revenue	180.8	153.2	18%	125.4	44%	480.3	378.5	27%
Raw material cost	63.3	48.0	32%	30.3	109%	153.5	95.0	62%
Operating expenses	41.4	36.4	14%	32.6	27%	110.6	94.7	17%
EBITDA	76.1	68.7	11%	62.5	22%	216.2	188.9	14%
EBITDA %	42.7%	45.3%		50.3%		45.6%	50.4%	
Depreciation costs	6.0	6.1	(2)%	4.7	28%	17.9	12.9	39%
Other Income	7.4	8.6		7.1		22.6	19.9	
PBT	77.6	71.2	9%	64.8	20%	220.9	195.8	13%
PBT %	43.5%	47.0%		52.1%		46.5%	52.3%	
PAT	58.0	53.5	8%	49.1	18%	166.1	145.3	14%
PAT %	32.6%	35.3%		39.5%		35.0%	38.8%	


SALES PROFILE – 9M FY22







- Performance chemicals Increased realizations across all products. Strong volume offtake for BHA during Q3 FY22 compared to Q3 FY21
- Pharma chemicals Increased volume offtake across products, improved realizations for DCC during Q3 FY22 compared to Q3 FY21
- FMCG chemicals Increased volume offtake and improved realizations for all key products in Q3 FY22 compared to Q3 FY21



- Exports continue to be key growth driver
- China market continues to be robust



COMPANY EVOLUTION

Focus on R&D and innovation has led to new product launches on a consistent basis



- In line with our vision, changed name to Clean Science and Technology
- Started manufacturing 4-MAP

 Started manufacturing Anisole using liquid phase technology

 Started manufacturing DCC Started manufacturing p-BQ and TBHQ



 Started manufacturing MEHQ and Guaiacol

- Started manufacturing BHA
- Started manufacturing Anisole using vapor phase technology in UNIT-2
- Started manufacturing AP
- Started manufacturing Anisole using vapor phase technology in UNIT-3
- Purchased 34 acre land for UNIT-4

KEY DIFFERENTIATORS





Among the largest producers globally of critical specialty chemicals with diversified applications

Multiple, automated manufacturing facilities with zero liquid discharge and strong focus on EHS

Unique, innovative, sustainable and cost-effective catalytic manufacturing process













Strategic process innovation and new product development driven by a strong in-house R&D team

Strong and long term relationships with a well diversified marquee customer base

Technocrat promoters supported by an experienced workforce with extensive domain knowledge Strong and consistent financial performance

STRONG IN-HOUSE R&D

R&D

Capabilities

Pioneered commercialization of catalytic-reactions in production processes



Designing catalysts to create new manufacturing processes and new products R&D Develop eco-friendly processes by eliminating use of toxic starting materials Strategy Focus on good Atom economy to avoid wastage Improve yields and selectivity in our existing processes R&D Expanding product portfolio across existing segments and adding new segments Focus Identifying products with high demand that only limited manufacturers produce globally State of the art technological equipment to develop, test and evaluate products

2 R&D units with 35 personnel (including 6 PhD's)

Government of India's Department of Scientific and Industrial Research recognized R&D units

TECHNOCRAT PROMOTERS

Promoters' sole business interest remains Clean Science and Technology with 78.51% stake





Ashok Boob Managing Director

Key functions: Projects, Manufacturing Capabilities Over 25 years of work experience in the chemical industry.

Previously worked as an Executive Director at Mangalam Drugs and Organics Ltd.

B.Chem. Engg. - ICT, Mumbai, India



Siddharth Sikchi Executive Director

Key functions: Marketing, R&D Over fourteen years of experience in the chemical industry.

M.Sc. – University of Manitoba, Canada.

B.Tech - ICT, Mumbai



Krishna Boob Executive Director

Key functions: Public relations, Purchase Close to two decades of expertise in the chemical industry.

Previously, worked as Director at Mangalam Drugs and Organics Ltd.

B.Pharma - University of Mumbai, India



Parth Maheshwari Vice President

Key functions: Business operations Over 5 years of work experience in the chemical industry.

MBA – Babson College B.Chem. Engg., Savitribai Phule University, India

ROBUST CORPORATE GOVERNANCE

Distinguished Board of Directors and reputed financial market reviewers







B.Sc, M.S. (MIT, USA), MBA (Columbia, USA)

Chairman - Sudarshan Chemicals



Prof. G. D. Yadav

Non-Executive, Independent Director

B.Chem. Engineering, Ph.D Technology



Sanjay Kothari

Non-Executive Director

B.Com (University of Calcutta)

Member of ICAI and ICSI



Keval Doshi

Non-Executive, Independent Director

B.Com. (University of Mumbai), Member of ICAI

Erstwhile Partner at Ernst & Young LLP



Madhu Dubhashi

Non-Executive, Independent Director

PG in Business Administration (IIM Ahmedabad)

Mr. Pradeep Rathi, Prof. G. D. Yadav, and Mr. Sanjay Kothari have been Board members for over a decade, reflecting our commitment towards long-term value creation for our business

Statutory Auditor

BSR & Co. LLP



Long term A+ (Stable) Short term A1+



Commercial Banking Partners





ERP System



DIVERSIFIED PRODUCT PROFILE





PRODUCT	APPLICATION	REVENUE (INR Crore)				
	PERFORMANCE CHEMICALS					
MEHQ (Monomethyl ether of hydroquinone)	 Polymerization inhibitor in acrylic acids, acrylic esters, super absorbent polymers (diapers and sanitary pads) Pre-cursor for agrochemical industry 	FY 2021 355 FY 2020 272				
> BHA (Butylated Hydroxy Anisole)	Anti-oxidant in food and animal feed industry	FY 2019 249 FY 2018 147				
> AP (L-Ascorbyl Palmitate)	Infant food formulations, breakfast cereals and cosmetics					
	PHARMACEUTICAL CHEMICALS	FY 2021 83				
➤ Guaiacol	Pre-cursor to manufacture APIs for cough syrup	FY 2020 64				
DCC (Dicyclohexyl Carbodiimide)	Reagent in anti-retroviral	FY 2019 FY 2018 50				
	FMCG CHEMICALS	FY 2021 63				
4-MAP (4-Methoxy Acetophenone)	Used in UV blocker in sunscreens (cosmetics industry)	FY 2020 67				
> Anisole	Precursor to perfumes, insect pheromones, pharmaceuticals	FY 2019 61 FY 2018 33				

FY 2021 REVENUE CONTRIBUTION









- Strong customer relationships and presence in export markets across multiple countries
- Strong contribution from high value critical performance chemicals segment.


STRONG FINANCIALS


Amongst the fastest growing and profitable specialty chemical companies globally

















COMMITMENT TOWARDS ESG





ENVIRONMENT (E)

- ✓ Among the few companies globally focused on developing "green", ecofriendly & cost competitive technologies using in-house catalytic processes
- ✓ Eco-friendly production processes ensures zero liquid discharge sites or only water as effluent
- ✓ Not received any material observations from pollution control board in India
- ✓ Power consumption from captive solar plants and investments in renewable energy projects



SOCIAL (S)

- ✓ Total contribution towards CSR activities during last 3 years is INR 8.1 crore
- ✓ Focus Areas -
- Education
- Healthcare
- Medical Relief
- Vocational Skills
- Environment Sustainability



CORPORATE GOVERNANCE (G)

- ✓ More than 1/3rd Board members are independent
- ✓ Statutory auditors BSR & Co.
- ✓ Long term & short term ratings by CRISIL are A+ (Stable) and A1+ respectively

DISCLAIMER



Certain statements and opinions with respect to the anticipated future performance of the company in the presentation ("forward - looking statements"), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to be correct. Such forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward - looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward - looking statements only speak as at the date the presentation is provided to the recipient and the company is not under any obligation to update or revise such forward -looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this presentation or that this presentation is suitable for the recipient's purposes. The delivery of this presentation does not imply that the information herein is correct as at any time subsequent to the date hereof and the company has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof